EN | UA
EN | UA

Help Support

Back

Lebrikizumab: Rapid relief and lichenification resolution in atopic dermatitis

Atopic dermatitis Atopic dermatitis
Atopic dermatitis Atopic dermatitis

What's new?

Lebrikizuma proved to have favourable outcomes for tough-to-treat atopic dermatitis, improving outcomes and quality of life.

In the realm of dermatology, atopic dermatitis (AD) presents as a troubling skin condition due to its multifaceted nature. Seeking to address this, a recent study investigated into the efficacy of Lebrikizumab, a promising monotherapy.

This examination, circling the ADvocate 1 and ADvocate 2 trials, focused on Lebrikizumab's impact on adults with AD with moderate-to-severe intensity. Over 16 weeks, Lebrikizumab at 250 mg dosage, was administered every two weeks and compared against a placebo.

Significant improvements were witnessed across various parameters. Notably, patients treated with Lebrikizumab exhibited a rapid and consistent reduction in AD severity across all body regions, including challenging areas like the head and neck.

The evaluation, conducted via the Eczema Area and Severity Index (EASI), exposed notable progress. By week 16, Lebrikizumab recipients demonstrated substantial enhancements in EASI scores, with improvements evident as early as week 2. In both trials, patients had significant symptom relief (erythema, oedema/papulation, excoriation [skin-picking] and lichenification [hard and thickened skin]), with improvements observed across all body regions.

Source:

Dermatology and Therapy

Article:

Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis

Authors:

Eric L. Simpson et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: